1 Supplementary figures





3

Supplementary figure 1: Initial sample comparison revealed two COVID-19 patients which were subsequently excluded in
 further analyses. A) Principal Component Analysis (PCA) graph comparing the COVID-19 patients with the influenza patients
 revealed two COVID-19 outliers (CoV0117 and CoV0271). B) Heatmap comparing the differentially expressed genes found
 specifically in COVID-19 patients indicates a different expression profile for CoV0117 and CoV0271 compared to the other
 samples. Assessment of the blood results indicates a high white blood cell count (C) and high lymphocyte count (D) in CoV0117
 and CoV0271. Subsequent, analysis of the patient metadata revealed that these samples are from two patients with known
 chronic lymphocytic leukaemia.

11



Supplementary figure 2: Sequence read depths obtained in the patients with COVID-19 or influenza in reads per million. A)
Comparison of the sequence read depths obtained in the 78 patients with COVID-19 (median sequence depth of 60.4 million)

16 reads) and 83 patients with influenza (median sequence depth of 58.9 million reads). B) Sequence read depths in the patients

17 with COVID-19 used for the comparison between survivors (median sequence depth of 62.6 million reads) and non-survivors

18 (median sequence depth of 55.7 million reads). Median sequence depths are illustrated by the black dashed line.

19

13





Supplementary figure 3: PCA analysis between patients with COVID-19 or influenza, and who survived or died of COVID 19. A) PCA analysis between patients with COVID-19 or influenza showing a substantial overlap between the two different
 group blood transcriptomes. B) A partial overlap of blood transcriptomes between patients who survived or who died of
 COVID-19.



26

27 Supplementary figure 4: GO Biological Process Term 'adaptive immune response' gene expression between patients with

28 **COVID-19 or influenza.** Unpaired non-parametric Wilcoxon test was used to assess the difference in abundancy of 83 29 immunoglobulin genes associated with the GO biological process term 'adaptive immune response' between patients with

immunoglobulin genes associated with the GO biological process term 'adaptive immune response' between patients with
 COVID-19 or influenza, a significant increase of these 83 immunoglobulin genes was detected in patients with COVID-19

31 compared to patients with influenza.

32



33

34 Supplementary figure 5: Significant difference in IRF7 abundancy between patients with COVID-19 or influenza. The mean

- 35 abundancy in patients with influenza is 1162 transcripts per million (TPM). This is significantly lower in patients with COVID-
- 36 19 at 861 TPM (p-value 7.60·10⁻⁰³). Statistical testing done with Wilcoxon test.





Cluster 1

COVID-19 survivors GO biological process term 'humoral immune response mediated by circulating immunoglobulin' (FDR p-value 2.23·10⁻⁴⁶)



Cluster 3 (brown)

COVID-19 non-survivors GO biological process term 'regulation of T-helper 1 cytokine production' (FDR p-value 4.24·10⁻⁰³)

Cluster 2 COVID-19 survivors GO biological process term 'nucleosome assembly' (FDR p-value 5.46·10⁻¹⁹)



Cluster 4 (magenta purple)

COVID-19 survivors GO biological process term 'regulation of T cell activation' (FDR p-value 4.51·10⁻⁰⁴)

- 38
- Supplementary figure 6: Top 4 clusters identified between COVID-19 survivors and non-survivors. For each cluster the predicted Gene Ontology (GO) biological process term identified by ToppGene are given, together with enrichment found in either COVID-19 survivors or non-survivors. From these top 4 clusters combinations of 100 genes were selected as potential
- 42 predictor variables of COVID-19 outcome using Boosted Logistic Regression, Bayesian Generalised Linear and RandomForest
- 43 models.
- 44